Malta - English - Malta Medicines Authority

nuron boitech b.v. - corynebacterium diphtheriae crm197 carrier protein; neisseria meningitidis polysaccharide group c; aluminium - suspension for injection - corynebacterium diphtheriae crm197 carrier protein 15 µg; neisseria meningitidis polysaccharide group c 10 µg; aluminium - vaccines

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f - pneumococcal infections; immunization - vaccines - active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to 17 years of age.active immunisation for the prevention of invasive disease caused by streptococcus pneumoniae in adults ≥18 years of age and the elderly.see sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes.the use of prevenar 13 should be determined on the basis of official recommendations taking into consideration the risk of invasive disease in different age groups, underlying comorbidities as well as the variability of serotype epidemiology in different geographical areas.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pneumococcal purified capsular polysaccharides, quantity: 2.2 microgram; pneumococcal purified capsular polysaccharides, quantity: 4.4 microgram - injection, suspension - excipient ingredients: aluminium phosphate; water for injections; polysorbate 80; diphtheria crm197 protein; succinic acid; sodium chloride - active immunisation for the prevention of pneumococcal disease caused by streptococcus pneumoniae serotypes 1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f and 23f in adults and children aged more than 6 weeks of age. the use of prevenar 13 should be guided by official recommendations.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pfizer manufacturing belgium n.v. - pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f) - suspension for injection - 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 4.4mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose

Canada - English - Health Canada

sanofi pasteur limited - meningococcal group a polysaccharide-tetanus toxoid conjugate; meningococcal group c polysaccharide-tetanus toxoid conjugate; meningococcal group y polysaccharide-tetanus toxoid conjugate; meningococcal group w polysaccharide-tetanus toxoid conjugate; tetanus toxoid - solution - 10mcg; 10mcg; 10mcg; 10mcg; 55mcg - meningococcal group a polysaccharide-tetanus toxoid conjugate 10mcg; meningococcal group c polysaccharide-tetanus toxoid conjugate 10mcg; meningococcal group y polysaccharide-tetanus toxoid conjugate 10mcg; meningococcal group w polysaccharide-tetanus toxoid conjugate 10mcg; tetanus toxoid 55mcg - vaccines

United Kingdom - English - myHealthbox

novartis vaccines and diagnostics - neisseria meningitidis group c (strain c11) oligosaccharide, corynebacterium diphtheriae crm197 protein , adsorbed on aluminium - suspension for injection - 10micrograms, 12.5 to 25.0micrograms, 0.3 to 0.4mg al 3+ - meningococcal vaccines - active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis group c.

United Kingdom - English - myHealthbox

novartis vaccines and diagnostics - neisseria meningitidis group c (strain c11) oligosaccharide, corynebacterium diphtheriae crm197 protein , adsorbed on aluminium - suspension for injection - 10micrograms, 12.5 to 25.0micrograms, 0.3 to 0.4mg al 3+ - meningococcal vaccines - active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis group c.

European Union - English - EMA (European Medicines Agency)

gsk vaccines s.r.l. - meningococcal group a, c, w-135 and y conjugate vaccine - immunization, meningitis, meningococcal - bacterial vaccines - prefilled syringe menveo is indicated for active immunisation of adolescents (from 11 years of age) and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations. vials menveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations.,

European Union - English - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningococcal - vaccines - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y.the use of this vaccine should be in accordance with available official recommendations.

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - meningococcal polysaccharide, serogroup a (monovalent conjugate); meningococcal polysaccharide, serogroup c (monovalent conjugate); meningococcal polysaccharide, serogroup w-135 (monovalent conjugate); meningococcal polysaccharide, serogroup y (monovalent conjugate); tetanus toxoid, filtered concentrate (carrier protein) - injection, solution - meningococcal polysaccharide, serogroup a (monovalent conjugate) 10 mcg/ 0.5 ml; meningococcal polysaccharide, serogroup c (monovalent conjugate) 10 mcg/ 0.5 ml; meningococcal polysaccharide, serogroup w-135 (monovalent conjugate) 10 mcg / 0.5ml; meningococcal polysaccharide, serogroup y (monovalent conjugate) 10 mcg/ 0.5 ml; tetanus toxoid, filtered concentrate (carrier protein) 55 mcg/ 0.5 ml